Symphony Allegro Overview
- Founded
- 2006

- Status
- Acquired/Merged
- Employees
- 1

- Latest Deal Type
- M&A
- Financing Rounds
- 2
Symphony Allegro General Information
Description
Developer of Alexza Pharmaceuticals' AZ-002 and AZ-004 products. The company was formed through a collaboration between Symphony Capital Partners and Alexza Pharmaceuticals to develop Alexza's AZ-002 Staccato Alprazolam and AZ-004 Staccato Loxapine programs. It supports AZ-002 through Phase IIb clinical trials for the treatment of panic attack in patients with panic disorder and AZ-004 through Phase IIb clinical trials for the treatment of acute agitation in patients with schizophrenia.
Contact Information
- 7361 Calhoun Place
- Suite 325
- Rockville, MD 20855
- United States
Symphony Allegro Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
This information is available in the PitchBook Platform. To explore Symphony Allegro‘s full profile, request access.
Request a free trialSymphony Allegro Executive Team (3)
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Frank Hurley Ph.D | Chief Executive Officer | ||
Daniel Salins | Chief Financial Officer | ||
Robert Smith Jr. | Treasurer |
Symphony Allegro Signals
Growth Rate

Growth

Size Multiple


Key Data Points
Twitter Followers
5.5k

Similarweb Unique Visitors
15.0K

Majestic Referring Domains
314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialSymphony Allegro Former Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
This information is available in the PitchBook Platform. To explore Symphony Allegro‘s full profile, request access.
Request a free trial